Literature DB >> 22018937

In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.

Céline Vidaillac1, Jorge Parra-Ruiz, Michael Joseph Rybak.   

Abstract

Oritavancin exhibited lower MIC(50) values (0.03 and 0.5 mg/L) than comparators against methicillin-resistant Staphylococcus aureus (MRSA, n = 50) and vancomycin-intermediate SA strains (n = 60). At subtherapeutic concentrations, oritavancin demonstrated rapid (within 9 h) and concentration-dependent bactericidal activity against daptomycin nonsusceptible (DNS) MRSA. Further investigations are warranted to determine the therapeutic potential of oritavancin against DNS MRSA.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22018937     DOI： 10.1016/j.diagmicrobio.2011.09.002

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  11 in total

1.  Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Authors:  Ronald N Jones; John D Turnidge; Greg Moeck; Francis F Arhin; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Authors:  Ronald N Jones; Greg Moeck; Francis F Arhin; Michael N Dudley; Paul R Rhomberg; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 4.  Oritavancin: a review in acute bacterial skin and skin structure infections.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 5.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

Review 6.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

7.  Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Authors:  Adam Belley; Francis F Arhin; Ingrid Sarmiento; Hong Deng; Warren Rose; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

8.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.

Authors:  Katie E Barber; Cortney E Ireland; Natalia Bukavyn; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2014-01-18

Review 10.  Periprosthetic joint infections: clinical and bench research.

Authors:  Laurence Legout; Eric Senneville
Journal:  ScientificWorldJournal       Date:  2013-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.